Dynamic Advisor Solutions LLC Has $1.12 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Dynamic Advisor Solutions LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 4.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 14,367 shares of the company’s stock after acquiring an additional 551 shares during the period. Dynamic Advisor Solutions LLC’s holdings in AstraZeneca were worth $1,119,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Bruce G. Allen Investments LLC lifted its stake in shares of AstraZeneca by 19.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after acquiring an additional 138 shares during the last quarter. Carnegie Investment Counsel lifted its stake in shares of AstraZeneca by 0.8% in the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares during the last quarter. Sunpointe LLC lifted its stake in shares of AstraZeneca by 4.5% in the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after acquiring an additional 147 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. lifted its stake in shares of AstraZeneca by 4.0% in the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company’s stock valued at $302,000 after acquiring an additional 149 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

AZN stock opened at $76.87 on Friday. The company has a market capitalization of $238.34 billion, a P/E ratio of 37.14, a price-to-earnings-growth ratio of 1.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business has a 50-day simple moving average of $81.45 and a two-hundred day simple moving average of $77.67.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.08 EPS. Research analysts expect that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is currently 47.34%.

Analysts Set New Price Targets

AZN has been the subject of several analyst reports. Barclays raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.